Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on NOVO NORDISK A/S
01/15 NOVO NORDISK A/S : - Share repurchase programme
01/12 NOVO NORDISK A/S : AS - Share repurchase programme
01/12 DIAGNOS : Announces the Management of the Flagship Nuevo Yo Program by Novo Nord..
01/10 Bond sell-off hits European shares but boost banks
01/10 NOVO NORDISK A/S : Team Novo Nordisk and Giessegi Srl Announce Partnership
01/10 NOVO NORDISK A/S : urges Ablynx board to negotiate acquisition
01/09 NOVO NORDISK A/S : Team Novo Nordisk and Giessegi Srl Announce Partnership
01/09 NOVO NORDISK A/S : Ozempic® approved in Canada for the treatment of adults with ..
01/09 Drug Firm Rejects $3.13 Billion Offer From Novo Nordisk -- WSJ
01/09 ABLYNX : dismisses EUR 2.6bn Novo Nordisk offer
01/08 Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid
01/08 NOVO NORDISK A/S : revises up offer for Ablynx to $3.1 billion
01/08 European shares hit highest since August 2015, Ablynx soars
01/08 Weak results weigh on FTSE 100, profit warning pummels Mothercare
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 NOVO NORDISK A/S : Share repurchase programme
01/08 Belgium's Ablynx Rejects EUR2.6 Billion Bid From Novo Nordisk
01/04 NOVO NORDISK A/S : Researchers from Novo Nordisk Detail Findings in Factor VIIa ..
01/04 NOVO NORDISK A/S : New Findings on Intercellular Junctions Described by Investig..
01/03 NOVO NORDISK A/S : - Status regarding Novo Nordisk's holding of its own shares
01/03 Allergan among companies unveiling price hikes
01/02 New drug approvals hit 21-year high in 2017
01/02 NOVO NORDISK A/S : Status regarding Novo Nordisk's holding of its own shares (31..
2017 NOVO NORDISK A/S : - Share repurchase programme
2017 NOVO NORDISK A/S : New Proinsulin Study Findings Have Been Reported by Researche..
2017 NOVO NORDISK A/S : Share repurchase programme
2017 NOVO NORDISK A/S : Beijing joins Cities Changing Diabetes program
2017 NOVO NORDISK A/S : Sunshine Holdings announces new appointment to Board of Direc..
2017 SUNSHINE : announces new appointment to director board
2017 U.S. tax cuts mix pleasure and pain for Europe's dollar earners
2017 NOVO NORDISK A/S : A S - Share repurchase programme
2017 NOVO NORDISK A/S : - Ozempic recommended for approval by the European regulatory..
2017 NOVO NORDISK A/S : AMGA Foundation Announces Participants in Obesity Care Model ..
2017 NOVO NORDISK A/S : Share repurchase programme
2017 NOVO NORDISK A/S : Lilly partners with Rimidi on digital diabetes management too..
2017 NOVO NORDISK A/S : Ozempic® (semaglutide) recommended for approval by the Europe..
2017 NOVO NORDISK A/S : Team Novo Nordisk Unveils New Kit and 2018 Roster
2017 NOVO NORDISK A/S : KU Leuven spin-out enters licence agreement with Novo Nordisk
2017 NOVO NORDISK A/S : A S - Share repurchase programme
2017 NOVO NORDISK A/S : Xultophy Offers Greater Blood Sugar and Body Weight Reduction..
2017 NOVO NORDISK A/S : Findings in Pharmacokinetics Reported from Novo Nordisk (Phar..
2017 NOVO NORDISK A/S : Receives FDA Approval of OZEMPIC® semaglutide Injection For t..
2017 NOVO NORDISK A/S : Prime Therapeutics Signs Outcomes-Based Contract with Novo No..
2017 TORRENT PHARMACEUTICALS : & Novo Nordisk India expand insulin manufacturing faci..
2017 NOVO NORDISK A/S : Team Novo Nordisk Unveils New Kit and 2018 Roster
2017 NOVO NORDISK A/S : reMYND out-licenses ReS39 to Novo
2017 TORRENT PHARMACEUTICALS : Novo Nordisk and Torrent expand insulin facility
2017 NOVO NORDISK A/S : (NVO) Position Lessened by Capital Bank & Trust Co
2017 TORRENT PHARMACEUTICALS : Novo Nordisk India and Torrent Pharma expand their ins..
2017 NOVO NORDISK A/S : Torrent Pharma expand insulin capacity in Gujarat by 35%
2017 TORRENT PHARMACEUTICALS : Ups production for danish company
2017 NOVO NORDISK A/S : Torrent expand gujarat facility
2017 NOVO NORDISK A/S : - Share repurchase programme
2017 NOVO NORDISK A/S : Shalamar Hospital launch mobile diabetes clinic
2017 NOVO NORDISK A/S : Mobile clinics to help battle diabetes
2017 NOVO NORDISK A/S : A S - Interim results of first-ever global survey show people..
2017 NOVO NORDISK A/S : A S - Ryzodeg significantly reduces the risk of low blood sug..
2017 NOVO NORDISK A/S : A S - Tresiba reduces hypoglycaemia regardless of blood sugar..
2017 NOVO NORDISK A/S : Ryzodeg Significantly Reduces Risk of Low Blood Sugar in Peop..
2017 NOVO NORDISK A/S : Tresiba Reduces Hypoglycaemia Regardless of Blood Sugar Level
2017 NOVO NORDISK A/S : Patent Application Titled "Alpha-1-Antitrypsin (A1AT) Fusion ..
2017 NOVO NORDISK A/S : aiming for blockbuster sales for FDA-approved semaglutide
2017 NOVO NORDISK A/S : Metacrine raises $22M series B
2017 NOVO NORDISK A/S : Switching to Tresiba Benefits People With Diabetes Irrespecti..
2017 NOVO NORDISK A/S : - Ozempic approved in the US
2017 NOVO NORDISK A/S : A S - Xultophy reported a better option than basal-bolus insu..
2017 NOVO NORDISK A/S : Receives FDA Approval of OZEMPIC (semaglutide) Injection For ..
2017 NOVO NORDISK A/S : bags first approval for once-weekly diabetes drug
2017 NOVO NORDISK A/S : Ryzodeg® significantly reduces the risk of low blood sugar in..
2017 NOVO NORDISK A/S : releases positive clinical data supporting insulin portfolio
2017 NOVO NORDISK A/S : Interim results of first-ever global survey show people with ..
2017 NOVO NORDISK A/S : FDA approves diabetes drug that also helps with weight loss
2017 NOVO NORDISK A/S : U.S. FDA Approves Novo Nordisk's Diabetes Treatment
2017 NOVO NORDISK A/S : Ozempic® (semaglutide) approved in the US
2017 NOVO NORDISK A/S : A S - Share repurchase programme
1  2  3  4  5  6  7  8  9  10Next
Financials ( DKK)
Sales 2017 112 B
EBIT 2017 49 247 M
Net income 2017 38 469 M
Finance 2017 18 482 M
Yield 2017 2,34%
P/E ratio 2017 21,55
P/E ratio 2018 20,30
EV / Sales 2017 5,69x
EV / Sales 2018 5,52x
Capitalization 657 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 319  DKK
Spread / Average Target -4,7%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S0.61%108 273
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987